share_log

Artemis Therapeutics Inc. (OTCMKTS:ATMS) Sees Large Decrease in Short Interest

Defense World ·  Nov 11, 2022 03:32

Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 700 shares, a decline of 61.1% from the October 15th total of 1,800 shares. Based on an average daily trading volume, of 2,400 shares, the days-to-cover ratio is presently 0.3 days.

Artemis Therapeutics Stock Performance

Artemis Therapeutics stock opened at $1.40 on Friday. Artemis Therapeutics has a 1 year low of $0.55 and a 1 year high of $5.00. The business has a 50-day moving average of $1.96 and a 200-day moving average of $2.49.

Get Artemis Therapeutics alerts:

Artemis Therapeutics Company Profile

(Get Rating)

Artemis Therapeutics Inc, a beauty company, develops and distributes skincare products in Israel. The company offers face serum with manuka honey and bee venom, face serum with enhanced vitamin C, day cream, night nourishing cream with manuka honey and nee venom, eye cream with manuka honey and bee venom, and face cleanser gel.

Featured Articles

  • Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
  • Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
  • Six Flags is a Ride You Don't Want to Get Stuck On
  • Hanesbrands May be Signaling a Bad Week for Retail Stocks
  • Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
  • Coupang Stock And Why You Should Care

Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment